Introduction
Histone deacetylases (HDACs) are frequently overexpressed in broad range of cancer types, where they alter cellular epigenetic programming to promote cell proliferation and survival. The class I HDACs are the most frequently overexpressed in cancers, particularly HDACs 1, 2 and 3 (Marks et al., 2001) . In prostate cancers, HDAC-1 is found to be overexpressed in approximately 70% of lesions (Weichert et al., 2008a) . The functional significance of HDAC overexpression is supported by the fact that HDAC inhibitors are proving to be effective anticancer agents in clinical practice. HDAC inhibitors are presently approved for treatment of advanced primary cutaneous T-cell lymphoma (Mann et al., 2007) and have been shown to be effective in animal models of prostate cancer (Qian et al., 2007; Wedel et al., 2008) . However, the mechanism by which HDACs become overexpressed in human cancers remains somewhat of a mystery.
To date miRNAs have been implicated in a wide range of cellular processes. Dysregulation of miRNA expression has been identified in a number of cancers (Pan et al., 2001; Lu et al., 2005; Volinia et al., 2006; Blenkiron et al., 2007; Chen and Stallings, 2007; Fulci et al., 2007; Gaur et al., 2007; Kummar et al., 2007; Meng et al., 2007; Porkka et al., 2007; Wedel et al., 2008) and an accumulating data indicate that some miRNAs can function as tumor suppressors or oncogenes and are important in cancer development. Deletion or loss of function of a tumor-suppressing miRNA results in overexpression of target oncogenes. Conversely, activation or overexpression of an oncogenic miRNA results in the silencing of tumor-suppressing target genes. The discovery of miRNAs at previously identified chromosomal breakpoints, deletion and amplification sites in certain cancers implies that they may be involved in disease initiation or progression.
Let-7, a family of miRNAs commonly downregulated in cancers, has been shown to regulate negatively the proto-oncogenes RAS and C-MYC (Hitomi et al., 2003; Mann et al., 2007) . Let-7 family members also target HMGA2, an oncogene known for its involvement in promoting the epithelial-mesenchymal transition (EMT) (Shell et al., 2007) . miR-15 and miR-16 promote apoptosis by suppressing expression of the antiapoptotic Bcl-2 protein and are commonly deleted in chronic lymphocytic leukemia (CLL), which leads to high levels of Bcl-2 expression (a prognostic indicator in CLL) (Volinia et al., 2006; Garcia-Manero et al., 2008) . miR34a has been shown in multiple studies to be regulated by the frequently mutated/deleted gatekeeper gene, p53. Activation of miR-34a by p53 normally promotes cell-cycle arrest through the modulation of E2F protein expression (He et al., 2007; Raver-Shapira et al., 2007; Tarasov et al., 2007) . Further, it was shown that introduction of miR-34a into cancer cells suppressed their growth in vivo, thereby demonstrating the potency of this tumor-suppressive miRNA (Tazawa et al., 2007) .
In this study, we found that miR-449a has growthsuppressing activity and obtained evidence that this activity results in large part through an inhibition of HDAC-1 expression. The genomic location of human miR-449a is chromosome 5q11.2, a region identified as a susceptibility locus in a variety of malignancies, including prostate cancer (Pan et al., 2001; Wiklund et al., 2003) . We found that miR-449a is frequently downregulated in prostate cancer tissues, relative to patientmatched control tissue. Our data suggest that miR-449a regulates prostate cancer cell growth in part by repressing the expression of HDAC-1. This is the first report documenting regulation of a class I HDAC by a growth-suppressing miRNA. We propose that the loss of miR-449a expression and the subsequent activation of HDAC-1 expression is a critical event in the epigenetic evolution of prostate cancer cells.
Results

Conservation of miR-449a
miR-449a is an evolutionary conserved miRNA throughout vertebrates with homologues in mammals, birds and amphibians. The UCSC human genome browser (Kent et al., 2002) Figure 1A) . The mature miR-449a sequence is identical in most mammals including the monkey, horse, rodents and dogs (Supplementary Figure 1B) . Similarly, the alternate strand is moderately conserved and maintains proper duplex formation; whereas the hairpin loop, which is cleaved off during maturation, has the lowest conservation. This computational analysis suggests that miR-449a is evolutionarily conserved and is therefore likely to have an important function across a variety of species.
miRNA families are frequently classified based on 7-to 8-mer nucleotide stretches, called seed sequences, located at the 5 0 -end of their mature sequence. Nearperfect complementarity between seed sequences and target transcripts is necessary for target recognition, whereas flanking sequence complementarity 'fine-tunes' target selection and/or enhances activity (Lewis et al., 2003 (Lewis et al., , 2005 Grimson et al., 2007) . Owing to high similarity in the seed sequence, it is believed that members of miRNA families share a similar function. Target Scan (Whitehead Institute, Cambridge, MA, USA) identified miR-34a, c and miR-449a, b as a single family of miRNAs in version 3.0, June 2006 (www. targetscan.org) due to the high similarity in their seed sequences. Interestingly, human miR-449a and miR34a, a known miRNA tumor suppressor, share identical seed sequences (Supplementary Figure 1C) .
Expression of miR-449a in prostate tumors and prostate cancer cell lines Expression of miR-449a was examined by real-time PCR in prostate tumor tissue and compared to normal patientmatched control tissue. In 9 of 12 tumor samples, miR449a was lower in tumors than patient-matched normal tissue (Figure 1 ). Prostate-specific antigen (PSA) did not correlate with relative expression (r ¼ À0.24, P ¼ 0.44) as determined by Pearson's correlation. We were unable to determine whether miR-449a expression had prognostic value because no mortalities have occurred in the subjects participating in this study and we do not have information Figure 1 miR-449a expression is lower in prostate tumors compared to patient-matched controls. Total RNA was extracted from punch biopsy samples taken from prostate tumor tissue and patient-matched controls. miRNA expression was analysed by real-time PCR and standardized to Small nuclear RNA U6 (snU6), which was used as the endogenous control. Relative miR-449a expression was determined in tumor tissue relative to patient-matched normal tissue. Results are displayed on a log scale. Figure 2A ). miR-449a was not inducible in the four remaining prostate cell lines (data not shown). Taken together, this data suggest that a decrease and/or loss of miR-449a expression may correlate with actively proliferating, immortalized or transformed prostate epithelial cells.
Introduction of miR-449a into PC-3 cells promotes an arrested phenotype To examine the physiological effect of miR-449a on cell growth, we transfected a metastatic prostate cancer cell line, PC-3 cells with miR-449a. As shown in Figure 2a , miR-449a caused drastic changes in cell morphology associated with growth arrest including increased size and a broad, flattened shape 3 days (72 h) following transfection. Such morphological changes were also observed when cells were transfected with a longer, dicer-dependent precursor miRNA (miR-449a-L). To further characterize the effect miR-449a had on cell growth, we analysed cell-cycle distribution in transfected cells by flow cytometry. Introduction of miR-449a or miR-449a-L caused a significant G 0 /G 1 arrest (n ¼ 3; Po0.01) and corresponding reductions in S (Po0.05) and G 2 /M (Po0.01) populations (Figures 2b and c) . In addition, the percent of cells in the subdiploid population was significantly increased (Po0.01) relative to controls (Figures 2b and d) . Overall, treatment with the nonspecific control miRNA (miR-CON) had no effect on cell morphology or cell-cycle distribution. We also transfected a longer, dicer-dependent nonspecific Function of miR-449a in prostate cancer EJ Noonan et al precursor miRNA, which had no effect on the cellular phenotype (data not shown).
HDAC-1 is a direct target of miR-449a
To find potential targets of miR-449a that would facilitate growth arrest, we used online search tools (that is, PicTar, Target Scan, miRanda) to identify putative target transcripts. Oncogenic proteins and/or genes involved in cell-cycle regulation were selected for analysis. Because all modes of miRNA-mediated gene repression result in decreased target protein levels (Pressman et al., 2007) , putative miR-449a targets were screened by immunoblot analysis (Supplementary Figure 3) . Among many such potential targets, HDAC-1 proved to be sensitive to miR-449a and a significant decrease (72%) in HDAC-1 protein levels was detected in miR-449a-transfected cells ( Figure 3b ). HDAC-1 expression was further analysed by real-time PCR. Compared with control treatments, mRNA levels of HDAC-1 were reduced by B60-70% in response to miR-449a transfection ( Figure 3c ). Taken together, these data suggest that miR-449a reduces HDAC-1 expression by inhibiting translation and/or causing mRNA instability/decay. HDAC-1 mRNA has a target site in its 3 0 UTR with high complementarity to miR449a (Figure 3a) . Overall, the sequence is 77.3% complementary to miR-449a, with a perfect match to the seed heptamer. Interestingly, this high complementary target sequence in the HDAC-1 transcript is unique compared to other HDAC mRNAs. Although the HDAC-8 transcript has an miR-449a target site, the complementarity is low, and immunoblotting data showed that HDAC-8 protein levels did not decrease following transfection with miR-449a (Supplementary Figure 4) . To determine if HDAC-1 mRNA is a direct target of miR-449a, we cloned the target sequence into the 3 0 UTR of a luciferase reporter vector (HDAC-1 3 0 UTR). Mutations, including a scramble of the seed target sequence (MUT1) and a scramble of the fulllength target site (MUT2) were also cloned into the reporter vector as controls. Co-transfection with miR449a, but not mock or the nonspecific control miRNA (miR-CON), specifically decreased luciferase activity in HDAC-1 3 0 -UTR samples, whereas both MUT1 and MUT2 fully rescued miR-449a repression of luciferase levels ( Figure 3e) .
We also co-transfected cells with miR-449a and a complementary oligo (anti-miR-449a) designed specifically to bind and sequester mature miR-449a. The antimiR-449a helped preserve HDAC-1 levels and generated a correlative decrease in p27 expression, whereas a nonspecific control oligo (anti-miR-Con) did not (Supplementary Figure 5) . Taken together, these results indicate that the HDAC-1 transcript is a direct target of miR-449a.
To determine if miR-449a regulates HDAC-1 expression in other prostate cancer cell lines, DU-145 cells were treated with miR-449a and protein levels were analysed by immunoblot. As shown in Figure 3d miR449a caused robust downregulation of HDAC-1 protein (81%) in DU-145 cells. We also examined expression of HDAC-1 mRNA in the human tissue samples from Figure 1 to determine if there was an inverse relationship between HDAC-1 and miR-449a expression. The relative level of HDAC-1 expression in normal versus tumor tissue is shown in Figure 3f . HDAC-1 expression was inversely correlated with miR-449a in 7 of the 12 samples tested (indicated by asterisks, Figure 3f ), further suggesting that miR-449a directly regulates HDAC-1 levels in prostate tissue.
Previous reports have shown that knockdown of HDAC-1 can lead to compensatory increases in the expression of other HDACs. To see if there were any changes in other HDAC proteins following HDAC-1 repression by miR-449a, we examined the protein levels of all other class I and class II HDACs in PC-3 cells. As shown in Supplementary Figure 4 , no change in class I HDAC (HDACs 2, 3 and 8) expression was observed in response to miR-449a. Class II HDACs 5, 6 and 7 were not detectable in PC-3 cells by immunoblot analysis.
Introduction of miR-449a and specific knockdown of HDAC-1 by siRNA elicit similar phenotypes of growth arrest To determine if miR-449a mediates its growth-repressing effects primarily through HDAC-1 knockdown, we treated PC-3 cells with siRNA specific to HDAC-1 (siHDAC-1). Immunoblot analysis confirmed specific knockdown of HDAC-1 by siRNA (Figure 4a ). siH-DAC-1-transfected cells showed an arrested phenotype similar to miR-449a treatments; cells arrested in G 0 /G 1 with corresponding reductions in S and G 2 /M populations (Figures 4b and c) . Knockdown of HDAC-1 also caused a subtle but reproducible increase in the subdiploid fraction (although the effect did not achieve statistical significance; Figures 4b and d) .
b-Galactosidase is a widely used marker for cellular senescence as it has been shown to correlate with an increased lysosomal mass during replicative senescence of human cells (Dimri et al., 1995; Kurz et al., 2000) . Decreased HDAC-1 levels have been associated with cellular senescence in previous reports (Wagner et al., 2001; Place et al., 2005) . Both miR-449a and siHDAC-1 induced a senescent-like phenotype in PC-3 cells, as determined by senescence-associated b-galactosidase activity (Figure 4e ). Although the morphological changes associated with miR-449a were not identical to siHDAC-1 treatments, HDAC-1 knockdown cells did assume a more flattened and rounded phenotype (Figure 4e ). Further, we also examined the effect of miR-449a on cancer cell clonogenicity (Supplementary Figure 6) . Mock-and miR-CON-transfected cells readily formed colonies. However, few colonies were detected following miR-449a or siHDAC-1 transfection (0 and 2, respectively). These data indicate that miR-449a or specific knockdown of HDAC-1 inhibits PC-3 clonogenicity and hence miR-449a could affect the ability of a single cell to form a tumor. These results also suggest that the growth-suppressive effects of miR-449a are in part facilitated by the downregulation of HDAC-1. P a t i e n t A P a t i e n t B P a t i e n t C P a t i e n t D P a t i e n t E P a t i e n t F P a t i e n t G P a t i e n t H P a t i e n t J P a t i e n t K P a t i e n t L P a t i e n t M HDAC-1 protein levels in PC-3 cells were assessed by immunoblotting following transfection with miR-449a and a nonspecific control (miR-CON) at 50 nM for 72 h. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used a loading control. (c) HDAC-1 mRNA levels in PC-3 cells were analysed by real-time PCR and standardized to the endogenous control GAPDH. Relative expression levels were determined for miR-CON and miR-449a-transfected samples. (d) DU-145 cells were transfected with miR-449a and a nonspecific control (miR-CON) at 50 nM for 72 h. HDAC-1 protein levels were examined by immunoblotting using GAPDH as a loading control. (e) 56 bp sequence from the HDAC-1 3 0 UTR containing the miR-449a target sequence (HDAC-1), or identical insert with a scrambled seed sequence (MUT1) or scrambled target sequence (MUT2) were cloned into the 3 0 UTR of a luciferase reporter construct. Constructs were cotransfected into PC-3 cells with a b-galactosidase control reporter vector, treated with mock (open bars), a nonspecific control (miR-CON, diagonal lines) or miR-449a (closed bars) and assayed for luciferase activity at 24 h. Luciferase activity was normalized to b-galactosidase and relative expression was determined for miR-CON and miR-449a-transfected samples. Statistical significance as compared to mock and miR-CON was determined for miR-449a treatment. miR-449a induces cell-cycle inhibitory protein p27 expression through downregulation of HDAC-1 HDAC-1 is known to inhibit the expression of the cellcycle inhibitory protein p27 (Lagger et al., 2002; Chen and Faller, 2005) . To determine if HDAC-1 repression by miR-449a induces p27, we transfected PC-3 cells with miR-449a or siHDAC-1 and evaluated p27 expression levels. As shown in Figure 5a , analysis of mRNA expression by real-time PCR indicated a profound induction in p27 levels after miR-449a or siHDAC-1 transfection. Compared with control treatments, both miR-449a and siHDAC-1 increased p27 mRNA levels by B3.2-and B4.2-fold, respectively. Immunoblot analysis further confirmed that introduction of miR449a or direct knockdown of HDAC-1 by siRNA activated p27 protein expression by 63 and 81%, respectively (Figure 5b ). p21 mRNA and protein expression does not change following introduction of miR-449a or siHDAC-1 (data not shown). As we found that miR-449a is induced in growth-arrested RWPE-1 and LNCaP cells, we examined expression of HDAC-1 and p27 mRNA levels under these conditions. In LNCaP cells, we found that increased miR-449a expression does not correlate with HDAC-1 levels. However, we see a subtle decrease in HDAC-1 and corresponding increase in p27 levels in contact-inhibited RWPE-1 cells, which does correlate with increased miR449a expression. These data provide additional evidence that growth arrest induced by miR-449a is mechanistically linked to its effect on HDAC-1 expression through induction of p27.
Discussion
Microarray studies have characterized the modulation of miRNA expression in prostate cancer as compared with normal prostate tissue and identified a number of miRNAs that are up-or downregulated in prostate tumors (Jiang et al., 2005; Mattie et al., 2006; Volinia et al., 2006; Gaur et al., 2007; Porkka et al., 2007; Ozen et al., 2008) . In all of these studies, miRNA expression profiles were based on the current databases of miRNAs known at the time (Volinia et al., 2006) . As there has been a steadily growing number of miRNAs identified over the past several years, these expression profiles analysed only a fraction of the number of miRNAs known today. miR449a was not identified in previous microarray studies examining prostate tissue/cell lines as earlier arrays used in these studies did not include miR-449a. We initially identified miR-449a as a promising target while screening for miRNAs that inhibited prostate cancer cell growth. As it has not been detected in other tumor cell lines or tissues we believe it may be a prostate-specific regulator of cell growth. We therefore further characterized its expression in tissue, associated phenotypes and identified one of its direct targets, HDAC-1. Overexpression of HDACs has been observed in a variety of different tumor types including gastric, colorectal, breast and prostate cancers (Kim et al., 2004; Zhang et al., 2005; Wilson et al., 2006; Weichert et al., 2008b) . HDACs have been shown to promote carcinogenesis by affecting EMT, causing dysregulation in the cell cycle and apoptosis, and promoting angiogenesis Figure 5 Histone deacetylase 1 (HDAC-1) target, p27, is induced following transfection with miR-449a. PC-3 cells were transfected with miR-449a, siHDAC-1 and a nonspecific control (miR-CON) at 50 nM for 72 h. (a) mRNA expression levels of HDAC-1 target, p27, were measured by real-time PCR and standardized to the endogenous control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). (b) Protein levels of p27 were determined by immunoblotting with GAPDH used as a loading control. (Kim et al., 2001; Mehnert and Kelly, 2007; Yoshikawa et al., 2007) . In prostate cancer, HDAC-1 overexpression has been noted in three different studies (Patra et al., 2001; Halkidou et al., 2004; Weichert et al., 2008a) . The question of how HDACs become overexpressed is still not entirely clear, but one possible mechanism is through regulation by miRNAs. In the case of HDAC-1, loss of miR-449a expression may contribute to HDAC-1 overexpression, and in 7 of the 12 tissue samples we see an inverse correlation between miR-449a and HDAC-1. miR-449a expression was lower in tumor tissue compared to normal patientmatched control tissue. The genomic location of human miR-449a is chromosome 5q11.2, a region identified as a susceptibility locus in prostate cancer (Pan et al., 2001; Wiklund et al., 2003) . Loss of miR-449a, an endogenous HDAC-1 inhibitor, may promote aberrant expression of HDAC-1 in prostate cancer contributing to the etiology of the disease.
HDAC inhibitors have been extensively studied in vitro for their widespread effects on gene expression in cancer cells resulting in reduced cell proliferation and apoptosis. In vivo studies in mouse prostate cancer models have revealed that HDAC inhibitors slowed tumor growth (Qian et al., 2007; Wedel et al., 2008) indicating an important function for HDACs in prostate cancer cell growth. We have found that miR-449a directly targets HDAC-1 resulting in decreased HDAC-1 mRNA and protein levels. In a previous study, knockdown of certain class I HDACs resulted in a compensatory increase in other family members (Lagger et al., 2002) . However, we did not observe global changes in either class I or class II HDAC expression by miR-449a. Furthermore, the miR-449a target site is unique to the HDAC-1 3 0 UTR indicating the specificity of miR-449a to HDAC-1. Much work has been done over the past few years studying the potential for small RNAs, including miRNAs, as therapeutics (reviewed in Tong and Nemunaitis (2008) ). Because a single miRNA has the potential to target a number of genes, miRNAs with potent tumor-suppressive function could be very useful in malignancies resulting from multiple genetic abnormalities. miR-449a and other miRNAs targeting HDACs may be ideal therapeutic targets for controlling aberrant HDAC expression.
siRNA studies have been crucial to understanding the importance of individual isoforms of class I HDACs and have helped characterize their function in proliferation and tumorigenesis (Wilson et al., 2006; Spurling et al., 2008; Weichert et al., 2008b) , including HDAC-1 (Glaser et al., 2003; Inoue et al., 2006; Senese et al., 2007) . In this study, we report that knockdown of HDAC-1, either by miR-449a or synthetic HDAC-1 siRNA, results in cell-cycle arrest, a senescent-like phenotype and loss of clonogenicity in PC-3 cells. Furthermore, we observed induction of cyclin-dependent kinase inhibitor p27, a known HDAC-1 target gene, which is directly involved in regulating cell proliferation. Although the cell-cycle profiles of miR449a and siHDAC-1 treatments are very similar, miR449a appears to have a more pronounced affect on cell viability as noted by the increased number of subdiploid cells in miR-449a treatments. Preliminary results show that miR-449a and specific knockdown of HDAC-1 promote a decrease in Bcl-2 protein levels, which most likely contributes to induction of apoptosis (data not shown). HDAC inhibitors have been shown to cause dysregulation of Bcl-2 family members and specifically promote a decrease in Bcl-2 levels in tumor cells (Duan et al., 2005; Kim et al., 2006; Iacomino et al., 2008) . However, although knockdown of HDAC-1 also causes a downregulation of Bcl-2, the Bcl-2 transcript contains putative targets sites for miR-449a. This indicates that the observed decrease in Bcl-2 expression in response to miR449a may be a result of direct targeting. Future investigation is warranted to determine the extent of the function of miR-449a in additional gene regulatory networks (that is, apoptosis). The notion that miR-449a has additional activities is further supported by the differences in morphology between miR-449a and siHDAC-1 transfectants. As miRNAs have the potential to target many genes, their effect on gene expression can be more complicated than that observed with specific siRNAs.
Downregulation of HDAC-1 has been shown to be associated with cellular senescence in human fibroblast cell lines suggesting that loss of HDAC-1 promotes a senescent-like phenotype (Wagner et al., 2001; Place et al., 2005) . HDAC inhibitors have also been shown to induce senescent-like phenotypes in a number of different transformed cell types including prostate cancer cells (Shabbeer et al., 2007; Xu et al., 2007) . The senescent-like phenotypes we observed with miR449a and siHDAC-1 are consistent with these previous reports. One might suspect that miR-449a is also important in tissue homeostasis. This idea is further supported by the observation that miR-449a is expressed in normal prostate tissue and expression of miR449a increases in RWPE-1 and LNCaP cell lines that have been artificially arrested (Supplementary Figure 2) . A decrease/loss of miR-449a expression may correlate with actively proliferating cells and could be involved in diseases associated with age-related tissue dysfunction.
miR-449a has high conservation across vertebrate species and is classified as a member of the miR-34 tumor suppressor family of miRNAs. This supports the idea that it has an important function and its deregulation may result in disease. Identification of growthsuppressing miRNAs (that is, miR-449a) is important for understanding cancer etiology, identifying prognostic markers and ultimately developing therapeutic agents. Future work on miR-449a involving regulation of its expression and further characterization of its growth-suppressing effects may lead to development of new therapeutic strategies for prostate cancer.
Materials and methods
miRNA/siRNA sequences A mature hsa-miR-449a mimic (miR-449a) and a nonspecific control (miR-CON) were synthesized by Invitrogen. All mature miRNA duplexes contained two-nucleotide 3 0 Function of miR-449a in prostate cancer EJ Noonan et al overhangs. A longer, dicer-dependent miR-449a precursor (referred to as miR-449a-L), a nonspecific precursor miRNA, a single-stranded miRNA inhibitor (antimiR) specific to miR449a and a nonspecific antimiR control were purchased from Ambion (Austin, TX, USA). Stealth siRNA targeting HDAC-1 (siHDAC-1) was synthesized by Invitrogen using BLOCK-iT RNAi Designer. All miRNA/siRNA sequences are listed in the Supplementary Table 1 .
Cell culture and miRNA/siRNA transfection PC-3, DU-145, BPH-1 and LNCaP human prostate carcinoma cell lines were grown in RPMI 1640 media and ND-1 cells in Dulbeco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, streptomycin (100 mg/ml), penicillin (100 U/ml), and maintained at 37 1C in a humidified, 5% CO 2 atmosphere. RWPE-1 cells were cultured in keratinocyte-serum-free medium supplemented with 5 ng/ml human recombinant epidermal growth factor, 0.05 mg/ml bovine pituitary extract, penicillin and streptomycin. For transfection, cultures were plated in antibiotic-free growth medium at a confluency of 25-30% approximately 24 h before transfection. miRNAs were transfected at a working concentration of 50 nM, using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) as described in Place et al. (2008) . Treatment proceeded for 72 h.
Prostate tissue isolation and RNA extraction Radical prostatectomy was performed by a surgeon and the specimen was transported fresh to the pathology department. A board-certified pathologist processed the specimen, according to protocol, within 30 min of removal of the specimen. The prostate was then sectioned and grossly normal and abnormal areas were identified by the pathologist. Samples were taken using a 5 mm punch biopsy and placed in separately labeled microcentrifuge tubes, snap-frozen in liquid nitrogen and stored at À80 1C. Total RNA was extracted using TRIzol reagent (Invitrogen) in conjunction with RNeasy RNA isolation kits (Qiagen, Velencia, CA, USA) according to the manufacturer's protocol. Pearson's correlation was used to determine correlation between PSA levels and relative miR-449 expression levels compared to patient-matched controls.
3
0 -UTR constructs/luciferase assay Complementary oligonucleotides containing the miR-449a target site from HDAC-1 (HDAC-1 3 0 UTR), a mutated miR-449a target seed sequence with identical flanking nucleotides (3 0 UTR-MUT1) and a nonspecific target sequence (3 0 UTR-MUT2) were synthesized by Invitrogen (see Supplementary Table 1 ). Oligonucleotides were annealed and ligated into the 3 0 UTR of the pMIR-REPORT luciferase reporter vector (Ambion). pMIR-REPORT Beta-gal was used as a control to monitor transfection efficiency. Constructs were cotransfected into PC-3 cells cultured in 24-well plates using Lipofectamine 2000. Briefly, 30 nM miRNA was transfected with 0.6 mg of the pMIR 3 0 -UTR clones and 0.4 mg of pMIR Beta-gal for 24 h. The Dual-Light System chemiluminescent reporter gene assay was used according to the manufacturer's protocol to quantify luciferase and b-galactosidase activity (Applied Biosystems, Foster City, CA, USA).
Analysis and quantification of miRNA expression Total RNA was extracted using the miRNeasy RNA isolation kit (Qiagen) according to the manufacturer's protocol. Total RNA (200 ng) was reverse transcribed using the TaqMan MicroRNA Reverse Transcription kit (Ambion) with miRNAspecific primers. To quantify the miRNA levels, the 7500 Fast Real-Time System (Applied Biosystems) was used in conjunction with gene-specific TaqMan assay kits (Applied Biosystems) for miR-449a and U6. U6 was used as an endogenous control to normalize expression. Relative miR-449a expression and standard error were calculated by the supplied Fast 7500 Real-Time System software.
